GlassScriptPhysician profile
Spencer Thomas Whealon
NPI 1740609148
$2,459.64
in general payments reported to CMS, 2019-2025
27 companies · $513 in 2025
The $513 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2021: $977 · 2022: $232 · 2023: $204 · 2024: $336 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,090.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $218.82 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.83 | 2019 | |
| Galvanize Therapeutics, INC | $133.83 | 2025 | Aliya System |
| Genzyme Corporation | $88.07 | 2024-2025 | |
| Insmed, INC. | $69.58 | 2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $66.73 | 2024-2025 | Tagrisso, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $60.34 | 2023-2025 | Dupixent |
| United Therapeutics Corporation | $52.33 | 2022-2023 | Tyvaso |
| Verona Pharma, INC. | $50.21 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $49.23 | 2024-2025 | Xolair |
| Mylan Specialty L.P. | $41.34 | 2023-2024 | Yupelri |
| Viatris Specialty LLC | $39.79 | 2025 | Yupelri |
| Amgen INC. | $38.71 | 2022-2025 | Tezspire |
| Electromed, INC. | $37.44 | 2024 | Smartvest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $37.34 | 2023 | Wakix |
| Philips North America LLC | $36.65 | 2025 | Vest Therapy Und |
| Inogen, INC. | $34.38 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Abbvie INC. | $24.90 | 2024 | |
| Vifor Pharma, INC. | $22.03 | 2024 | Zemaira |
| Bayer Healthcare Pharmaceuticals INC. | $18.79 | 2022 | |
| Boston Scientific Corporation | $18.78 | 2023 | |
| Daiichi Sankyo INC. | $15.51 | 2025 | Enhertu |
| Erbe USA INC | $15.00 | 2023 | |
| Circassia INC. | $14.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2022 | |
| Pulmonx Corporation | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Whealon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.